Merck Says Keytruda Cut Progression or Death Risk 43% in Trial
Merck reported a 43% reduction in progression or death risk with Keytruda in a trial for dMMR endometrial cancer.
Story updates
03:36:32 PM UTC
SquawkNews
Merck reported Phase 3 KEYNOTE—C93 met its primary endpoint in dMMR advanced/recurrent endometrial cancer: pembrolizumab cut risk of progression or death by 43% vs platinum chemo (HR=0.57; p=0.0002). Median PFS was 38.2 months vs 8.4 months. OS trend positive; follow-up ongoing.Material DetailsCont…
03:37:53 PM UTC
SquawkNews
KEYNOTE-C93 met its primary endpoint, with pembrolizumab monotherapy improving progression-free surv